Download presentation
Presentation is loading. Please wait.
Published byAmice Chandler Modified over 5 years ago
1
Erectile Dysfunction and Cardiovascular Disease: Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men With Both Conditions Ajay Nehra, MD Mayo Clinic Proceedings Volume 84, Issue 2, Pages (February 2009) DOI: / Copyright © 2009 Mayo Foundation for Medical Education and Research Terms and Conditions
2
FIGURE Erectile function and return to normal rates after PDE5 inhibitor use in men with erectile dysfunction and hypertension (top), erectile dysfunction and diabetes (middle), and hyperlipidemia/dyslipidemia (bottom). Numbers inside bars represent medication doses in milligrams. B = baseline; CG = comorbid group; IIEF = International Index of Erectile Function; P = placebo; PDE5 = phosphodiesterase type 5; RG = reference group; S = sildenafil; T = tadalafil; V = vardenafil. Mayo Clinic Proceedings , DOI: ( / ) Copyright © 2009 Mayo Foundation for Medical Education and Research Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.